The HUS1 checkpoint clamp component (HUS1), which is a member of an evolutionarily conserved, genotoxin-activated checkpoint complex (Rad9-Rad1-Hus1 [9-1-1] complex), is involved in cell cycle arrest and DNA repair in response to DNA damage. We conducted this study to investigate the biological significances of HUS1 expression in hepatocellular carcinoma (HCC) development. The mRNA and protein expression levels of HUS1 were determined using Real-time PCR and Western blot, respectively. One hundered and twenty four paraffin sections from HCC tissues were analyzed by immunohistochemistry to assess the association between HUS1 expression and clinicopathological characteristics of patients. The Kaplan-Meier method was performed to calculate the OS and RFS curves. Cell proliferation and colony formation assays, cell migration and invasion assays and cell cycle assays were used to determine the suppressor role of HUS1 in vitro. A mouse model was used to determine the effect of HUS1 on tumorigenesis. The expression of HUS1 was significantly decreased in HCC cell lines and tissues, and low HUS1 expression was associated with poor prognosis of HCC patients. Upregulation of HUS1 expression inhibited the cell proliferation, colony formation, migration, and invasion, as well as arrested cell cycle at G0/G1 in HCC cells in vitro. Moreover, sufficient HUS1 expression inhibited the tumor growth in nude mice.
available for the treatment of HCC, including hepatectomy, liver transplantation, transcatheter hepatic arterial chemoembolization (TACE), partial ablation, radiation therapy, targeted therapy, and immunotherapy. [1] [2] [3] However, due to the insidious early symptoms, rapid tumor progression, and controversial strategies of combining various therapies, more than 70% of advanced HCC patients do not improve survival with the abovementioned therapies. [6] [7] [8] Identifying the intracellular molecular alterations involved in HCC development and progression is crucial for understanding the mechanisms of hepatocarcinogenesis and for improving the clinical outcomes of HCC patients. 9, 10 One of the mechanisms of tumorigenesis is the abundant accumulation of intracellular DNA lesions and mutations. How mammalian cells respond to various types of DNA damage is a critical determinant of whether an individual develops a tumor. [11] [12] [13] [14] [15] Activation of the DNA damage checkpoint is an important molecular mechanism triggered in mammalian cells in response to DNA lesions.
Once the DNA lesion occurs, the checkpoint proteins arrest the cell cycle to promote DNA repair or induce apoptosis in the damaged cells, thereby preventing the accumulation of genomic insults and avoiding the passage of damaged DNA to daughter cells. If cellular DNA damage is ignored, the resultant genomic instability could form certain endogenous sources that lead to premature aging, developmental defects, or tumorigenesis. 16 In the cellular ATR-dependent checkpoint pathway, Hus1 can form a heterotrimeric complex with Rad1 and Rad9
(9-1-1 complex). The crystal structure of 9-1-1 is a closed circular ring in which the C-terminal domain of one protein interacts with the N-terminal domain of the following protein in the order of Rad9 → Hus1 → Rad1. [17] [18] [19] This complex acts as a putative sensor of the ATR-dependent signal pathway. Once loaded on DNA strains, this complex initiate signal transduction to promote the phosphorylation of the substrates involved in the ATR-Chk1 pathway, such as Chk1, Rad17, and Rad9, and then regulates the cell cycle, replication, or repair machineries. [19] [20] [21] [22] [23] Signaling defects in the 9-1-1 components in cells are associated with the failure of a certain checkpoint activation that restrains late-origin firing in response to DNA damage. [23] [24] [25] It has been well known that RAD9 (a member of the 9-1-1) is an oncogene in many cancer types. Aberrant RAD9 expression has been linked to breast, lung, thyroid, and prostate tumorigenesis and is a poor prognostic factor for cancer patients. [26] [27] [28] [29] However, the relationship between HUS1 expression and tumorigenesis has rarely been reported. To date, only Javier et al 30 have indicated that high HUS1 expression may be a poor prognostic factor for ovarian cancer, while the role of HUS1 in HCC development has not been studied.
In this study, we aim to explore HUS1 expression and its prognostic value in HCC patients. Further analyses of the biological functions of HUS1 in HCC cell lines were also included in our study.
| MATERIALS AND METHODS

| Cell lines and culture
The human HCC cell lines HepG2 and Hep3B were obtained from American Type Culture Collection (ATCC; Manassas, VA); the Huh7 cell line was obtained from the RIKEN cell bank (Ibaraki, Japan); the were determined according to the Union for International Cancer Control (UICC). The postoperative follow-up visits of the enrolled patients were conducted by our outpatient department. The follow-up visits consisted of clinical and laboratory examinations and were performed every 3 months during the first 2 years, every 6 months during the next 2 years, and then annually for an additional 5 years or until death, whichever occurred first. OS and RFS were adopted as measures of the patients' prognoses. The OS was calculated from the time of the specimen collection (ie, surgery) to the time of death or the final follow-up. The RFS was defined as the time from the date of surgery to the date of the first detectable recurrence or the final follow-up. The patients enrolled in this study were informed of the study aim and significance, and the study was approved by the Ethics
Committee of the Sun Yat-sen University Cancer Center.
| Extraction of total RNA and RT-qPCR
Total RNA was extracted from the 57 freshly frozen paired tissue samples using a QIAGEN total RNA isolation kit (Tiangen, Beijing, China) according to the manufacturer's protocol. Then, the quantity and concentration of the total RNA were assessed by absorbency at 260 nm using a NanoDrop™ spectrophotometer (ND-1000; Thermo
Fisher Scientific, Wilmington, DE). Reverse transcription was conducted using GoScript™ Reverse Transcriptase (Promega, Beijing, China) following the manufacturer's recommendations.
To compare the differences in the mRNA expression of HUS1
between the tumor and adjacent non-tumor liver tissues, RT-qPCR Accordingly, the samples were divided into the following two groups:
the low HUS1 expression group (described as "−" and "+") and the high HUS1 expression group (described as "++"and "+++"). 
| RNA oligonucleotides and cell transfections
Knockdown of HUS1 in the HCC and normal hepatic cell lines was performed using two different types of small interfering RNAs (siRNAs) that specifically targeted HUS1(siHUS1). A negative control siRNA (siNC)
was also prepared. The siRNAs were synthesized by GenePharma. A total of 2 × 10 5 SMMC-7721 and Hep3B cells were seeded in six-well plates, respectively. Transfection was carried out with 600 pmol siHUS1 or siNC using Lipofectamine RNAi MAX reagent (Invitrogen, Shanghai, China) under serum-free conditions for 8 h, then the medium was changed and the HCC cells were incubated for further analyses.
| Colony formation and cell proliferation assays
For the colony formation assay, the cells transfected with LV-HUS1, LV-NC, siHUS1 or siNC were plated in a six-well plate at a density of 500 cells/2 mL per well and placed in a humid environment of 5% CO2 at 37°C for 14 days. The cell communities in the plates were washed gently with PBS, fixed in 75% alcohol for 10 min, and stained with 0.5% crystal violet for 30 min. Cell masses that contained >50 cells were defined as a colony.
The colony-forming efficiency (CFE, %) was calculated as follows: 
| Cell cycle assay
Flow cytometry was performed for the cell cycle analysis using propidium iodide (PI). Proper cells were collected and washed twice with cold PBS prior to fixation in 75% ethanol at −20°C overnight.
Next, the Bel-7402, HepG2, SMMC-7721, and Hep3B were washed twice with cold PBS and then incubated with RNase at 37°C for 30 min.
Then, 400 μl PI reagent (Bestbio, Shanghai, China) were added to each sample for staining in the dark for 30 min. Finally, the distribution of the cell cycle was determined using a flow cytometer (Beckman Coulter; Fullerton, CA, USA) according to the user manual.
| Cell migration and invasion assays
The cell migration and invasion assays were performed using a 24-well The migration or invasion efficiency was observed by light microscopy as follows: 10 visual fields were randomly selected for each well (30 fields in total) to calculate the average value of the transferred cells.
Each experiment was conducted in triplicate. independently at least three times in this study. Significant differences were expressed as the mean ± standard deviation (SD). All tests were twosided, and a P-value <0.05 was considered statistically significant. Significantly improved OS and RFS of patients were observed in high HUS1 expression group than that in low HUS1 expression HUS1 group (P = 0.003 and P = 0.019, respectively; log-rank test)
3 | RESULTS
| Low expression of HUS1 in human HCC tissues and cell lines
We first detected the HUS1 transcription levels in 57 pairs of tumor tissues and matched adjacent non-tumor tissues. A real-time quantitative PCR analysis was performed to determine the mRNA quantity of HUS1 and revealed that this quantity was lower in the HCC tumor tissues than that in the adjacent non-tumor tissues (P < 0.01; Figure 1A ). Based on this result, we next detected the protein expression of HUS1 by performing a Western blot analysis. The results
showed that the expression of the HUS1 protein in the HCC tumor tissues was significantly lower than that in the adjacent non-tumor tissues of 44 paired tissues (P < 0.001; Figure 1B) . These results (Table 1) . According to the χ 2 analysis, the expression of HUS1 was associated with the histological grade (P = 0.048) and serum AFP (P = 0.048) but not with age, gender, tumor number, tumor size, tumor capsule, HBsAg, or TNM stage (Table 1 ).
| Correlation between low HUS1 expression and poor prognosis in HCC patients
A Kaplan-Meier survival analysis was adopted to evaluate the prognostic value of HUS1 and showed that the median overall survival (OS) time and median recurrence-free survival (RFS) time of the patients in the high HUS1 expression group were 67 and 64 months, respectively, while those of the patients in the low HUS1 expression group were 33 and 16 months. The 5-year OS and RFS rates were 57.7% and 51.3% in the high HUS1 expression group compared with 38.6% and 30.0% in the low HUS1 expression group, respectively, (log-rank test, P = 0.003 and P = 0.019, respectively; Figure 2B ). Thus, patients with reduced HUS1 expression levels had significantly shorter OS times and a greater propensity for disease recurrence. According to the univariate Cox regression analysis, the HUS1 expression and histological grade were significantly associated with the OS (Table 2) ; the HUS1 expression and serum AFP were significantly associated with the RFS in the HCC patients (Table 3 ). In further multivariate Cox regression analyses, the expression of HUS1 was an independent prognostic factor of OS (P = 0.009; Table 2 ) and RFS (P = 0.038; Table 3 ) in the HCC patients. with LV-NC, the cell cycle was arrested at G0/G1 in HCC cells transfected with LV-HUS1 ( Figure 3D) . Consistently, the percentage of cells at the S and G2/M phases was decreased in the LV-HUS1-transfected Bel-7402 and HepG2 cell lines ( Figure 3D ). This variation was consistent with previous studies demonstrating that the DNA damage checkpoint causes cell cycle arrest when addressing DNA damage in cancers. 5, 6 Altogether, the expression of HUS1 prevented the proliferation of tumor cells during HCC development.
| Effect of HUS1 overexpression on the migration and invasion of HCC cells
In order to further explore the effects of HUS1 on cell function, we subsequently explored the roles of HUS1 in cell migration and invasion in HCC cell lines. In the cell migration assays, both Bel-7402 and HepG2 cells transfected with LV-HUS1 showed a diminished migration ability compared with that of corresponding cells transfected with LV-NC ( Figure 3E) . Moreover, the cell invasion assays
showed that the overexpression of HUS1 significantly prevented cell invasion into the lower compartment through a Matrigel-coated chamber ( Figure 3F ). Therefore, sufficient HUS1 expression may inhibit cancer metastasis to a certain extent in patients with HCC.
Furthermore, our results support the cancer suppressor bio-function of HUS1 during HCC development.
| HUS1 suppresses tumorigenesis of HCC in vivo
To detect the impact of HUS1 in tumor growth in vivo, the Bel-7402
and HepG2 cells transfected with LV-HUS1 and LV-NC were injected subcutaneously into nude mice. At the end of observation, the results showed that HUS1 overexpression in Bel-7402 and HepG2 cells significantly delayed the tumor growth in mice ( Figure 4A ). Specifically, the mean tumor volume in the HUS1 overexpressed group was significantly smaller than that in the control group (366.7 mm 3 vs 1058.0 mm 3 for Bel7402, 129.0 mm 3 vs 360.7 mm 3 for HepG2).
Consistently, the mean tumor weight in the HUS1 overexpressed group was notably smaller than that in the control group (0.330 vs 0.981 g for Bel7402, 0.318 vs 0.518 g for HepG2; Figure 4C ). The 
| DISCUSSION
Once DNA damage occurs in mammalian cells, the DNA checkpoint is activated to stop the replication process and allow DNA repair or, alternatively, to trigger apoptosis to remove the severely damaged cells. [13] [14] [15] [16] The ATR-dependent pathway is an important damagecheckpoint pathway in which the Rad9-Rad1-Hus1 (9-1-1) complex acts as a putative sensor of optimal ATR signaling. This complex can promote the phosphorylation of important substrates, such as Chk1, Rad17, and Rad9, in the ATR pathway, which is required for the inhibition of DNA synthesis after DNA damage. [17] [18] [19] [20] Among studies Previous studies indicated that the 9-1-1 complex mediated a cellular S-phase retardation 32, 33 ; however, our data showed that sufficient HUS1 expression arrested HCC cells at G0/G1. This difference may be due to the various cancer species, in which the checkpoint arrests may occur in different phases in tumor cell lines. Previous studies suggest that abundant DNA lesions exist in aggressive neoplasms, and, in response, a higher level of checkpoint proteins exists in malignant tumors. 14, 15 However, in our study, the expression of HUS1 in HCC is significantly lower than that in normal All data are shown as the mean ± SD of three independent experiments. P-values were calculated using the independent Student's t-test. *, P < 0.05 versus siNC; **, P < 0.01 versus siNC; ***, P < 0.001 versus siNC liver tissues and cells. This finding is consistent with the result in which skin cells are null for checkpoint protein RAD9 in skin carcinoma. [34] [35] [36] [37] Considering the mechanisms of the DNA checkpoint pathway, we presume that cells with fewer checkpoint proteins are highly susceptible to genotoxin-induced tumorigenesis because of the resultant genomic instability, inability to properly process damaged DNA, and/or improper regulation of cell cycle progression after incursion. Based on the abovementioned experimental results and theories, we confirm that the checkpoint protein HUS1 contributes to tumor inhibition in HCC.
| CONCLUSIONS
In summary, we confirmed that the down-regulated HUS1 expression level in HCC and revealed the relationship between lower HUS1 levels and unfavorable outcomes in HCC patients. . The data are shown as the mean ± SD of three independent experiments. P-values were calculated using the independent Student's t-test. *, P < 0.05 versus siNC; **, P < 0.01 versus siNC; ***, P < 0.001 versus siNC
